Sultan Ayesh Mohammed Saghir, Amir M Al Hroob, Salah A Alshehade, Sulaiman Alnaimat, Nuha A Al Yousfi, Sarah Ahmad Bahjat Al-Rawashdeh, Mohammad Ahmad Al Rawashdeh, Mohammed Abdullah Alshawsh
{"title":"自身免疫性疾病中生物标志物发现和临床应用的蛋白质组学方法。","authors":"Sultan Ayesh Mohammed Saghir, Amir M Al Hroob, Salah A Alshehade, Sulaiman Alnaimat, Nuha A Al Yousfi, Sarah Ahmad Bahjat Al-Rawashdeh, Mohammad Ahmad Al Rawashdeh, Mohammed Abdullah Alshawsh","doi":"10.1016/j.cca.2025.120533","DOIUrl":null,"url":null,"abstract":"<p><p>Autoimmune diseases (ADs) impact approximately 3% of the global population. It encompasses more than 80 chronic, often debilitating conditions resulting from immune system defects that lead the body to attack its tissues. Although many ADs are rare, their prevalence is rising. Despite advancements, ADs diagnosis and classification still rely heavily on clinical examination combined with conventional laboratory testing and imaging. Emerging proteomic screening, technologies now offer the potential to identify unique biomarkers for more precise diagnosis, classification, and treatment decisions. Protein profiling, an advancing area within proteomics, provides unparalleled insights into biological processes underlying these diseases. Thus, this review highlights recent developments in proteomic and genetic profiling for ADs pathogenesis, diagnosis, and treatment challenges, focusing on the clinical utility of proteomic techniques in prognosis, diagnosis, and therapeutic guidance. Notably, discovering new biomarkers through proteomic screening is crucial for creating robust multi-parameter assays, which enhance diagnostic accuracy and treatment decisions in ADs.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120533"},"PeriodicalIF":2.9000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Proteomic approaches for biomarker discovery and clinical applications in autoimmune diseases.\",\"authors\":\"Sultan Ayesh Mohammed Saghir, Amir M Al Hroob, Salah A Alshehade, Sulaiman Alnaimat, Nuha A Al Yousfi, Sarah Ahmad Bahjat Al-Rawashdeh, Mohammad Ahmad Al Rawashdeh, Mohammed Abdullah Alshawsh\",\"doi\":\"10.1016/j.cca.2025.120533\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Autoimmune diseases (ADs) impact approximately 3% of the global population. It encompasses more than 80 chronic, often debilitating conditions resulting from immune system defects that lead the body to attack its tissues. Although many ADs are rare, their prevalence is rising. Despite advancements, ADs diagnosis and classification still rely heavily on clinical examination combined with conventional laboratory testing and imaging. Emerging proteomic screening, technologies now offer the potential to identify unique biomarkers for more precise diagnosis, classification, and treatment decisions. Protein profiling, an advancing area within proteomics, provides unparalleled insights into biological processes underlying these diseases. Thus, this review highlights recent developments in proteomic and genetic profiling for ADs pathogenesis, diagnosis, and treatment challenges, focusing on the clinical utility of proteomic techniques in prognosis, diagnosis, and therapeutic guidance. Notably, discovering new biomarkers through proteomic screening is crucial for creating robust multi-parameter assays, which enhance diagnostic accuracy and treatment decisions in ADs.</p>\",\"PeriodicalId\":10205,\"journal\":{\"name\":\"Clinica Chimica Acta\",\"volume\":\" \",\"pages\":\"120533\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2026-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica Chimica Acta\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cca.2025.120533\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cca.2025.120533","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
Proteomic approaches for biomarker discovery and clinical applications in autoimmune diseases.
Autoimmune diseases (ADs) impact approximately 3% of the global population. It encompasses more than 80 chronic, often debilitating conditions resulting from immune system defects that lead the body to attack its tissues. Although many ADs are rare, their prevalence is rising. Despite advancements, ADs diagnosis and classification still rely heavily on clinical examination combined with conventional laboratory testing and imaging. Emerging proteomic screening, technologies now offer the potential to identify unique biomarkers for more precise diagnosis, classification, and treatment decisions. Protein profiling, an advancing area within proteomics, provides unparalleled insights into biological processes underlying these diseases. Thus, this review highlights recent developments in proteomic and genetic profiling for ADs pathogenesis, diagnosis, and treatment challenges, focusing on the clinical utility of proteomic techniques in prognosis, diagnosis, and therapeutic guidance. Notably, discovering new biomarkers through proteomic screening is crucial for creating robust multi-parameter assays, which enhance diagnostic accuracy and treatment decisions in ADs.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.